The Clinical Study of Acute Pancreatitis Treated by TongFuSan

NCT ID: NCT02204189

Last Updated: 2014-07-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-31

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether TongFuSan is effective in the treatment of acute pancreatitis with gastrointestinal dysfunction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Patient who is diagnosed with acute pancreatitis(AP) should be included.
* Patients will be divided into two groups as random number table: control group(A) and experimental group(B).
* Group A will be given Mosapride po,and group B will be given TongFusan except for basic treatments of AP.
* Same investigator will write the case report form.
* Investigator will collect the patients' blood in three points: on admission, the third day and the seventh day.
* Otherwise, we need write down patients' clinical manifestation,Traditional Chinese Medicine differentiation, the result of clinical tests.
* When the patient discharge, we will write down the treatment measures, therapeutic effect, length of stay and the costs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pancreatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TongFuSan

TongFuSan 1g per time, change every day, the duration is seven days

Group Type EXPERIMENTAL

TongFuSan

Intervention Type DRUG

TongFuSan 1g

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TongFuSan

TongFuSan 1g

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinical diagnosis of acute pancreatitis,both mild type and severe type

Exclusion Criteria

* pregnant or suckling
* cancer in late time
* patient near death
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Friendship Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

miaobin

associate chief physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bin Miao, PHD

Role: STUDY_CHAIR

Beijing Friendship Hospital

Hong Wang, Graduate

Role: STUDY_DIRECTOR

Beijing Friendship Hospital

Shuwen Zhang, bachelor

Role: STUDY_DIRECTOR

Beijing Friendship Hospital

Chao Wang, PHD

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Yanli Su, PHD

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Shirong Li, graduate

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Fengwu Li, graduate

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Dinghua Xu, graduate

Role: PRINCIPAL_INVESTIGATOR

Beijing Friendship Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Friendship Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hong You, PHD

Role: CONTACT

010-63139197

Bin Miao, PHD

Role: CONTACT

18612252085

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hong You, PHD

Role: primary

010-63139197

Wanzhen Xu, PHD

Role: backup

010-63138049

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

z141100002114004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.